The C3G/Rap1 pathway promotes secretion of MMP-2 and MMP-9 and is involved in serous ovarian cancer metastasis

Cancer Letters

Volumn 359, Issue 2, 2015, Pages 241-249

  Che, Ya Ling ^a,c   Luo, Shu Juan ^a,d   Li, Gang ^a   Cheng, Min ^a   Gao, Yi Meng ^a   Li, Xue Mei ^a   Dai, Jie Min ^a   He, Huan ^a   Wang, Jin ^a   Peng, Hui Juan ^a   Zhang, Yu ^a   Li, Wen Yan ^a   Wang, Hui ^a   Liu, Bin ^b   Linghu, Hua ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c Department of Obstetrics and Gynecology ^*  (China)

^d Department of Ultrasound   (China)

Author keywords

C3G; Metastasis; Rap1 activity; Serous ovarian cancer

Indexed keywords

CRK SH3 DOMAIN BINDING GUANINE NUCLEOTIDE RELEASING FACTOR; GELATINASE A; GELATINASE B; INITIATION FACTOR; RAP1 PROTEIN; UNCLASSIFIED DRUG; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TELOMERE BINDING PROTEIN; TERF2IP PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CELL INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; ENZYME ACTIVATION; ENZYME REGULATION; ENZYME RELEASE; EXTRAVASATION; FEMALE; GENE SILENCING; HEY CELL LINE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; OVARY CARCINOMA; PERITONEUM METASTASIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEROUS OVARY CANCER; SIGNAL TRANSDUCTION; SKOV3 CELL LINE; TREATMENT FAILURE; TUMOR DIFFERENTIATION; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; DISEASE FREE SURVIVAL; ENZYMOLOGY; METABOLISM; MORTALITY; NEOPLASM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; SECONDARY; SECRETION (PROCESS); UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; DISEASE-FREE SURVIVAL; FEMALE; GUANINE NUCLEOTIDE-RELEASING FACTOR 2; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TELOMERE-BINDING PROTEINS;

EID: 84923107683     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.01.019     Document Type: Article

References (39)

1. Lalwani N., Prasad S.R., Vikram R., Shanbhogue A.K., Huettner P.C., Fasih N. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Radiographics 2011, 31:625-646.
2. Elattar A., Bryant A., Winter-Roach B.A., Hatem M., Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst. Rev 2011, (8). CD007565.
3. Braicu E.I., Sehouli J., Richter R., Pietzner K., Lichtenegger W., Fotopoulou C. Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome. Eur. J. Cancer 2012, 48:687-694.
4. Heasman S.J., Ridley A.J. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol 2008, 9:690-701.
5. Sit S.T., Manser E. Rho GTPases and their role in organizing the actin cytoskeleton. J. Cell Sci 2011, 124:679-683.
6. Bos J.L., Rehmann H., Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 2007, 129:865-877.
7. Cherfils J., Zeghouf M. Regulation of small GTPases by GEFs, GAPs, and GDIs. Physiol. Rev 2013, 93:269-309.
8. Freeman S.A., McLeod S.J., Dukowski J., Austin P., Lee C.C., Millen-Martin B., et al. Preventing the activation or cycling of the Rap1 GTPase alters adhesion and cytoskeletal dynamics and blocks metastatic melanoma cell extravasation into the lungs. Cancer Res 2010, 70:4590-4601.
9. McSherry E.A., Brennan K., Hudson L., Hill A.D., Hopkins A.M. Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase. Breast Cancer Res 2011, 13:R31.
10. Gotoh T., Hattori S., Nakamura S., Kitayama H., Noda M., Takai Y., et al. Identification of Rap1 as a target for the Crk SH3 domain-binding guanine nucleotide-releasing factor C3G. Mol. Cell. Biol 1995, 15:6746-6753.
11. Radha V., Mitra A., Dayma K., Sasikumar K. Signalling to actin: role of C3G, a multitasking guanine-nucleotide-exchange factor. Biosci. Rep 2011, 31:231-244.
12. Voss A.K., Gruss P., Thomas T. The guanine nucleotide exchange factor C3G is necessary for the formation of focal adhesions and vascular maturation. Development 2003, 130:355-367.
13. Ishimaru S., Williams R., Clark E., Hanafusa H., Gaul U. Activation of the Drosophila C3G leads to cell fate changes and overproliferation during development, mediated by the RAS-MAPK pathway and RAP1. EMBO J. 1999, 18:145-155.
14. Radha V., Rajanna A., Gupta R.K., Dayma K., Raman T. The guanine nucleotide exchange factor, C3G regulates differentiation and survival of human neuroblastoma cells. J. Neurochem 2008, 107:1424-1435.
15. Shivakrupa R., Radha V., Sudhakar C., Swarup G. Physical and functional interaction between Hck tyrosine kinase and guanine nucleotide exchange factor C3G results in apoptosis, which is independent of C3G catalytic domain. J. Biol. Chem 2003, 278:52188-52194.
16. Arai A., Nosaka Y., Kohsaka H., Miyasaka N., Miura O. CrkL activates integrin-mediated hematopoietic cell adhesion through the guanine nucleotide exchange factor C3G. Blood 1999, 93:3713-3722.
17. Hirata T., Nagai H., Koizumi K., Okino K., Harada A., Onda M., et al. Amplification, up-regulation and over-expression of C3G (CRK SH3 domain-binding guanine nucleotide-releasing factor) in non-small cell lung cancers. J. Hum. Genet 2004, 49:290-295.
18. Okino K., Nagai H., Nakayama H., Doi D., Yoneyama K., Konishi H., et al. Inactivation of Crk SH3 domain-binding guanine nucleotide-releasing factor (C3G) in cervical squamous cell carcinoma. Int. J. Gynecol. Cancer 2006, 16:763-771.
19. Samuelsson J., Alonso S., Ruiz-Larroya T., Cheung T.H., Wong Y.F., Perucho M. Frequent somatic demethylation of RAPGEF1/C3G intronic sequences in gastrointestinal and gynecological cancer. Int. J. Oncol 2011, 38:1575-1577.
20. Tsuda M., Tanaka S. Roles for crk in cancer metastasis and invasion. Genes Cancer 2012, 3:334-340.
21. Hasegawa H., Kiyokawa E., Tanaka S., Nagashima K., Gotoh N., Shibuya M., et al. DOCK180, a major CRK-binding protein, alters cell morphology upon translocation to the cell membrane. Mol. Cell. Biol 1996, 16:1770-1776.
22. Kiyokawa E., Hashimoto Y., Kobayashi S., Sugimura H., Kurata T., Matsuda M. Activation of Rac1 by a Crk SH3-binding protein, DOCK180. Genes Dev 1998, 12:3331-3336.
23. Gao Y.M., Zhang Y., Li W.Y. Role of C3G/Rap1 and Dock180/Rac1 signal pathway in infiltration of ovarian cancer. J. Third Mil. Med. Univ 2012, 34:1031-1034.
24. Luo S.J., Che Y.L., Peng H.J. Expression of C3G in epithelial ovarian cancer and its role in proliferation of SKOV3 cells. J. Third Mil. Med. Univ 2013, 35:1471-1474.
25. Shaw T.J., Senterman M.K., Dawson K., Crane C.A., Vanderhyden B.C. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol. Ther 2004, 10:1032-1042.
26. Chen H., Wu X., Pan Z.K., Huang S. Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis. Cancer Res 2010, 70:9979-9990.
27. Ramirez N.E., Zhang Z., Madamanchi A., Boyd K.L., O'Rear L.D., Nashabi A., et al. The alpha(2)beta(1) integrin is a metastasis suppressor in mouse models and human cancer. J. Clin. Invest 2011, 121:226-237.
28. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3:453-458.
29. Poveda A., Kaye S.B., McCormack R., Wang S., Parekh T., Ricci D., et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol. Oncol 2011, 122:567-572.
30. Tarin D., Price J.E., Kettlewell M.G., Souter R.G., Vass A.C., Crossley B. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 1984, 44:3584-3592.
31. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
32. Karam A., Dorigo O. MMPs in ovarian cancer as therapeutic targets. Anticancer Agents Med. Chem 2012, 12:764-772.
33. Chang S.J., Hodeib M., Chang J., Bristow R.E. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol. Oncol 2013, 130:493-498.
34. Fan T., Zhao Q., Chen J.J., Chen W.T., Pearl M.L. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol. Oncol 2009, 112:185-191.
35. Kenny H.A., Lengyel E. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle 2009, 8:683-688.
36. Roomi M.W., Monterrey J.C., Kalinovsky T., Rath M., Niedzwiecki A. In vitro modulation of MMP-2 and MMP-9 in human cervical and ovarian cancer cell lines by cytokines, inducers and inhibitors. Oncol. Rep 2010, 23:605-614.
37. Wu X., Li H., Kang L., Li L., Wang W., Shan B. Activated matrix metalloproteinase-2 - a potential marker of prognosis for epithelial ovarian cancer. Gynecol. Oncol 2002, 84:126-134.
38. Brabek J., Constancio S.S., Siesser P.F., Shin N.Y., Pozzi A., Hanks S.K. Crk-associated substrate tyrosine phosphorylation sites are critical for invasion and metastasis of SRC-transformed cells. Mol. Cancer Res 2005, 3:307-315.
39. Nagini S. RECKing MMP: relevance of reversion-inducing cysteine-rich protein with kazal motifs as a prognostic marker and therapeutic target for cancer (a review). Anticancer Agents Med. Chem 2012, 12:718-725.